| Trial ID: | L3836 |
| Source ID: | NCT01823510
|
| Associated Drug: |
Ticagrelor + Aspirin
|
| Title: |
Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01823510/results
|
| Conditions: |
Type-2 Diabetes Mellitus|Coronary Artery Disease
|
| Interventions: |
DRUG: Ticagrelor + Aspirin|DRUG: Clopidogrel + Aspirin
|
| Outcome Measures: |
Primary: Thrombus Formation, Thrombus formation in Badimon Perfusion Chamber high-shear) (ex vivo model of thrombosis)., up to 7 days | Secondary: Platelet Reactivity, Platelet reactivity by Multiplate Analyzer, up to 7 days|P2Y12 Reaction Unit (PRU), Platelet reactivity by measuring P2Y12 Reaction Unit using Accumetrics VerifyNow, up to 7 days|Platelet Reactivity Index (PRI), Platelet reactivity index by Vasodilator-Stimulated Phosphoprotein phosphorylation (VASP) assay., up to 7 days
|
| Sponsor/Collaborators: |
Sponsor: Juan J Badimon | Collaborators: AstraZeneca
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
20
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2013-07
|
| Completion Date: |
2016-05-10
|
| Results First Posted: |
2017-09-01
|
| Last Update Posted: |
2017-12-08
|
| Locations: |
Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01823510
|
